Transfection of HEK cells via DNA-loaded PLGA and P(FASA) nanospheres
HEK cells were transfected with the GFP gene using various vectors: naked DNA, lipofectamine, and both PLGA and P(FASA) plasmid-loaded nanospheres. All methods were assessed alone and with the use of chloroquine, a lysosomal enzyme inhibitor. Transfection efficiencies were determined and compared at various times post-incubation using a fluorescence standard curve. Neither naked DNA alone nor naked DNA and chloroquine were capable of transfecting cells. No differences were evident between lipofectamine with chloroquine and lipofectamine alone which transfected cells with a constant increase in efficiency up to 2 weeks. While transfection was not feasible with polymeric nanospheres alone, the addition of chloroquine allowed DNA released from nanospheres within cells to escape endosomal degradation and transfect the cells. The increase in transfection efficiency via nanospheres over time was exponential up to 1 week, as compared to the constant rate seen for the bolus-type administration of lipofectamine, indicating that nanospheres delivered DNA to the cells by a controlled release mechanism. Additionally, the effective dose delivered to cells via nanospheres was approximately 25% that of lipofectamine, indicating that transfection via PLGA and P(FASA) nanospheres might actually be more efficient.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2002 |
|---|---|
| Erschienen: |
2002 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of drug targeting - 10(2002), 6 vom: 28. Sept., Seite 497-506 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sandor, M [VerfasserIn] |
|---|
| Themen: |
1SIA8062RS |
|---|
| Anmerkungen: |
Date Completed 16.04.2003 Date Revised 06.11.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM123531861 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM123531861 | ||
| 003 | DE-627 | ||
| 005 | 20231222201551.0 | ||
| 007 | tu | ||
| 008 | 231222s2002 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0412.xml |
| 035 | |a (DE-627)NLM123531861 | ||
| 035 | |a (NLM)12575740 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sandor, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transfection of HEK cells via DNA-loaded PLGA and P(FASA) nanospheres |
| 264 | 1 | |c 2002 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2003 | ||
| 500 | |a Date Revised 06.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a HEK cells were transfected with the GFP gene using various vectors: naked DNA, lipofectamine, and both PLGA and P(FASA) plasmid-loaded nanospheres. All methods were assessed alone and with the use of chloroquine, a lysosomal enzyme inhibitor. Transfection efficiencies were determined and compared at various times post-incubation using a fluorescence standard curve. Neither naked DNA alone nor naked DNA and chloroquine were capable of transfecting cells. No differences were evident between lipofectamine with chloroquine and lipofectamine alone which transfected cells with a constant increase in efficiency up to 2 weeks. While transfection was not feasible with polymeric nanospheres alone, the addition of chloroquine allowed DNA released from nanospheres within cells to escape endosomal degradation and transfect the cells. The increase in transfection efficiency via nanospheres over time was exponential up to 1 week, as compared to the constant rate seen for the bolus-type administration of lipofectamine, indicating that nanospheres delivered DNA to the cells by a controlled release mechanism. Additionally, the effective dose delivered to cells via nanospheres was approximately 25% that of lipofectamine, indicating that transfection via PLGA and P(FASA) nanospheres might actually be more efficient | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 7 | |a Polymers |2 NLM | |
| 650 | 7 | |a Polylactic Acid-Polyglycolic Acid Copolymer |2 NLM | |
| 650 | 7 | |a 1SIA8062RS |2 NLM | |
| 650 | 7 | |a Polyglycolic Acid |2 NLM | |
| 650 | 7 | |a 26009-03-0 |2 NLM | |
| 650 | 7 | |a Lactic Acid |2 NLM | |
| 650 | 7 | |a 33X04XA5AT |2 NLM | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 700 | 1 | |a Mehta, S |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, J |e verfasserin |4 aut | |
| 700 | 1 | |a Thanos, C |e verfasserin |4 aut | |
| 700 | 1 | |a Weston, P |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, J |e verfasserin |4 aut | |
| 700 | 1 | |a Mathiowitz, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g 10(2002), 6 vom: 28. Sept., Seite 497-506 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2002 |g number:6 |g day:28 |g month:09 |g pages:497-506 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2002 |e 6 |b 28 |c 09 |h 497-506 | ||